Arena Pharmaceuticals Initiates Second And Third Pivotal Trials Evaluating Lorcaserin For The Treatment Of Obesity

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for weight management in overweight and obese patients. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 15th, 2007